Your session is about to expire
← Back to Search
Platinum-based compound
Chemotherapy for Choroid Plexus Cancer
Phase 1
Recruiting
Led By Mark Souweidane, M.D.
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Subjects with a histologically confirmed diagnosis of ACPP or CPC that is newly diagnosed, residual or recurrent
Subjects must have normal organ and marrow function documented within specific parameters
Must not have
Females who are pregnant or lactating
Subjects who are receiving any other anticancer or investigational agents
Timeline
Screening 3 weeks
Treatment Varies
Follow Up around 7 weeks after intra-arterial chemotherapy
Awards & highlights
No Placebo-Only Group
Summary
This trial will test if delivering cancer drugs directly to brain tumors through blood vessels is safe and effective for patients with specific types of brain tumors. The goal is to shrink the tumors.
Who is the study for?
This trial is for individuals with a specific type of brain tumor, either newly diagnosed, remaining after treatment, or returned. They must be relatively active (able to care for themselves), have normal body functions as tested recently, and not be on increasing doses of steroids. Pregnant women and those with serious unrelated illnesses or taking certain other drugs are excluded.
What is being tested?
The study tests intra-arterial chemotherapy using Melphalan, Carboplatin, and Topotecan in patients before they undergo a second surgery. The goal is to see if this approach safely shrinks the tumors and improves surgical outcomes.
What are the potential side effects?
Potential side effects may include reactions at the infusion site, decreased blood cell counts leading to increased infection risk or bleeding problems, nausea or vomiting from the chemo drugs used.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My diagnosis is ACPP or CPC, whether it's new, remaining, or has come back.
Select...
My organ and bone marrow functions are normal.
Select...
I have been on a stable or decreasing dose of dexamethasone for at least one week.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am not pregnant or breastfeeding.
Select...
I am not currently taking any cancer treatment or experimental drugs.
Select...
I have seizures that are not controlled by medication.
Select...
I recently had a bone marrow transplant.
Select...
I have a brain tumor called CPP or I have water on the brain causing symptoms.
Select...
My cancer has spread to multiple locations.
Select...
I am taking medication for seizures that affects how other drugs work.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ around 7 weeks after intra-arterial chemotherapy
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~around 7 weeks after intra-arterial chemotherapy
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Other study objectives
Extent of pathology correlation to tumor vascularity and tumor viability
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Intra-arterial ChemotherapyExperimental Treatment3 Interventions
Subjects are pre-treated with heparin, and then given single doses of Melphalan, Carboplatin, and Topotecan consecutively via intra-arterial infusion. Multiple arteries may be used, with the total dose of the drugs remaining the same.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Melphalan
2008
Completed Phase 3
~1500
Carboplatin
2014
Completed Phase 3
~6120
Topotecan
2017
Completed Phase 3
~2460
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Intra-arterial chemotherapy for Choroid Plexus Papilloma involves the direct delivery of chemotherapeutic agents to the tumor site via arteries. This approach maximizes the local concentration of the drug at the tumor, enhancing its efficacy in reducing tumor size while minimizing systemic exposure and associated side effects.
This is particularly beneficial for CPP patients as it can improve the outcomes of subsequent surgeries and reduce the risk of adverse effects, thereby maintaining the overall health and quality of life of the patients.
Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review.
Treatment of adult brainstem glioma with combined antiangiogenic therapy: a case report and literature review.
Find a Location
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
1,082 Previous Clinical Trials
1,138,193 Total Patients Enrolled
Mark Souweidane, M.D.Principal InvestigatorWeill Medical College of Cornell University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am not pregnant or breastfeeding.I can care for myself but may need occasional help.I am not currently taking any cancer treatment or experimental drugs.My diagnosis is ACPP or CPC, whether it's new, remaining, or has come back.My organ and bone marrow functions are normal.I have seizures that are not controlled by medication.My neurological symptoms have been stable for at least a week.I recently had a bone marrow transplant.I have been on a stable or decreasing dose of dexamethasone for at least one week.I have a brain tumor called CPP or I have water on the brain causing symptoms.My cancer has spread to multiple locations.I am at high risk for irregular heartbeats or QT prolongation.I meet the specific criteria for previous therapies.I am taking medication for seizures that affects how other drugs work.
Research Study Groups:
This trial has the following groups:- Group 1: Intra-arterial Chemotherapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger